Fibromyalgia Treatment Market Overview

Fibromyalgia (FM) conditions arise due to the accidental impact, lasting excruciated muscle pain and fatigue. Although there is no cure for FM, treating its symptoms can make the condition manageable. It is treated by prescribing antidepressants to reduce pain and improve sleep. Simultaneously, other treatments such as counseling, CBT (cognitive behavior therapy) exercises and relaxation techniques are suggested to benefit in reducing pain and muscles tension.

Cases of road accidents have been rising at an alarming rate, leading to increasing the prevalence of fibromyalgia and hence the demand for effective treatments of FM. Simultaneously, prevailing psychiatric disorders and post-traumatic stress disorders also act as risk factors, increasing the fibromyalgia cases. Therefore, the Fibromyalgia Treatments market is growing pervasively on the global platform.

Traumatic stress and road accidents can be among the major factors that can promote the Fibromyalgia Treatment Market in the coming years. The psychiatric disorder can also trigger such cases. In a journal published by the Pain Research and Management Journal, in 2014, researchers said that physical trauma often is followed by fibromyalgia. Rheumatic diseases play a pivotal role as well. These diseases affect joints more, and as its direct impact, muscles can show signs of fibromyalgia. However, Chinese treatments are fast becoming popular which can inspire the fibromyalgia treatment market in exploring previously uncharted territories. 

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1879

KEYPLAYERS

Prominent players engaged in the fibromyalgia treatment market, as are Pfizer, Johnson & Johnson Services, Inc., GlaxoSmithKline, Astellas Pharma, AstraZeneca, F. Hoffmann-La Roche AG, SANOFI, Eli Lilly and Company, Jazz Pharmaceuticals, Bayer AG, ALLERGAN, AbbVie, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, ABBOTT, NOVARTIS, and others.

In 2018, researchers at the Optics and Photonics Research Center described that laser light and therapeutic ultrasound in low intensity, when applied on the palm, can reduce the pain of fibromyalgia by 75%.

FDA approved the commercialization of IMC-1, which is a combination of famciclovir, an antiviral agent, and celecoxib, an anti-inflammatory. The medicine showed great signs in improving fibromyalgia.

Fibromyalgia Treatment Market Segmentation

MRFR has segmented the report into three key dynamics for an easy grasp and enhanced understanding:-

By Treatments     : Comprises - Targeted (Anti-depressant & Anti-Seizure Drug), and Symptomatic Treatment among others. 

By Diagnosis        : Laboratory Evaluation and Presence of Central Sensitization among others. 

By End Users       : Hospitals & Clinics, Research Centers, and Laboratories among others.

By Regions           :  North America, Europe, APAC and Rest of the World.

The Anti-Seizure Drugs segment holds the largest share in the FM market

Fibromyalgia Treatment Market Regional Analysis

Regional Analysis:

Globally North America leads the Fibromyalgia Treatments market with the significant market share. The Market is expected to grow phenomenally during 2017 to 2023. Attributing to the favorable reimbursement scenario and greater expenditure on healthcare the market is expected to perceive a healthy growth. Another important driver for the regional market growth is the rapid uptake of new technologies in the US. Furthermore, rising cases of chronic rheumatic diseases coupled with the rising awareness among people foster the market growth in the region.

Europe emerging as a lucrative Fibromyalgia Treatments market will grow at a phenomenal CAGR.  The resurging economy in the region is expected to foster the regional market growth, increasing per capita healthcare expenditures. The financial support provided by private and governments bodies for R&D activities and new improved reimbursement policies in healthcare will fuel the Fibromyalgia Treatment market in Europe.

Asia Pacific market for the Fibromyalgia Treatments is expected to perceive the fastest growth by 2023 at a modest CAGR during 2017 to 2023. India and China backed by the huge population and the availability of low-cost drugs for the treatment will lead the market growth.

Moreover, the rapidly growing healthcare sector coupled with the large unmet needs over the forecast period will provide impetus to the market growth. Vietnam, Thailand, and Malaysia among other South East Asian countries are projected to contribute significantly to the regional market growth. Besides the growing penetration of healthcare insurance is expected to drive the Fibromyalgia Treatments market in the in the Asia Pacific region.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/fibromyalgia-treatments-market-1879

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com